文献速递核素与放射性配体治疗放射性药物与辐射防护

SPECT/CT图像衍生的红骨髓吸收剂量与接受[177Lu]Lu-DOTATATE治疗患者的血液学毒性相关

SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [177Lu]Lu-DOTATATE.
PubMed 文献 · J Nucl Med · 2024-05-01

本研究纳入20例接受4个周期[177Lu]Lu-DOTATATE治疗的神经内分泌肿瘤患者,采用人工智能驱动的SPECT/CT多时间点红骨髓剂量学及蒙特卡洛模拟,评估红骨髓吸收剂量与血液学毒性的关联。结果显示,腰椎和胸椎红骨髓吸收剂量中位数与6个月随访时血小板相对基线下降显著相关(如腰椎中位剂量r=-0.72,P=0.0038),提示红骨髓吸收剂量可能有助于理解和管理肽受体放射性核素治疗中的血液学毒性。

要点

  • 20例神经内分泌肿瘤患者接受4周期[177Lu]Lu-DOTATATE治疗,视野内腰椎和胸椎红骨髓吸收剂量中位数范围为0.019-0.11 Gy/GBq。
  • 4周期累积吸收剂量中位数为1.3 Gy(范围0.6-2.5 Gy),血液学毒性总体轻微,血小板、中性粒细胞和血红蛋白均无2级及以上毒性。
  • 6个月随访时血小板相对基线分数值为74%,且与红骨髓吸收剂量显著相关(腰椎中位剂量r=-0.72,P=0.0038)。

核心结论

  • 本研究发现图像衍生的红骨髓吸收剂量与血液学毒性显著相关,包括6个月随访时血小板的相对下降。
  • 这些发现表明红骨髓吸收剂量可能用于理解和管理肽受体放射性核素治疗中的血液学毒性。

研究设计与样本

  • 纳入20例接受4个治疗周期[177Lu]Lu-DOTATATE治疗的神经内分泌肿瘤患者。
  • 采用人工智能驱动工作流程在视野内分割椎体海绵骨,结合含海绵骨微结构模型的院内宏观/微观蒙特卡洛代码进行多时间点177Lu SPECT/CT红骨髓剂量学估算。
  • 将视野内腰椎和胸椎红骨髓吸收剂量视为全身红骨髓吸收剂量的代表,与每周期后约8周及全部周期完成后3个月和6个月随访时的血液学毒性标志物进行相关性分析。

主要发现

  • 视野内腰椎和胸椎红骨髓吸收剂量中位数(D median,vertebrae)范围为0.019-0.11 Gy/GBq。
  • 全部4周期累积吸收剂量中位数为1.3 Gy(范围0.6-2.5 Gy)。
  • 血液学毒性总体轻微,血小板、中性粒细胞和血红蛋白均无2级及以上毒性;但血细胞计数随时间下降,6个月时血小板、中性粒细胞、淋巴细胞和血红蛋白相对基线的分数值分别为74%、97%、57%和97%。
  • 治疗期间及3个月和6个月随访时,部分血液学毒性标志物与红骨髓吸收剂量之间存在统计学显著相关。
  • 6个月随访时血小板计数相对基线:D median,vertebrae(r=-0.64,P=0.015)、D median,lumbar(r=-0.72,P=0.0038)、D median,thoracic(r=-0.58,P=0.029)、D average,vertebrae(r=-0.66,P=0.010);其中D median,lumbar和D median,thoracic分别为视野内腰椎和胸椎红骨髓中位吸收剂量,D average,vertebrae为所有椎体质量加权平均吸收剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematologic toxicity, although often transient, is the most common limiting adverse effect during somatostatin peptide receptor radionuclide therapy. This study investigated the association between Monte Carlo-derived absorbed dose to the red marrow (RM) and hematologic toxicity in patients being treated for their neuroendocrine tumors. Methods: Twenty patients each receiving 4 treatment cycles of [177Lu]Lu-DOTATATE were included. Multiple-time-point 177Lu SPECT/CT imaging-based RM dosimetry was performed using an artificial intelligence-driven workflow to segment vertebral spongiosa within the field of view (FOV). This workflow was coupled with an in-house macroscale/microscale Monte Carlo code that incorporates a spongiosa microstructure model. Absorbed dose estimates to RM in lumbar and thoracic vertebrae within the FOV, considered as representations of the whole-body RM absorbed dose, were correlated with hematologic toxicity markers at about 8 wk after each cycle and at 3- and 6-mo follow-up after completion of all cycles. Results: The median of absorbed dose to RM in lumbar and thoracic vertebrae within the FOV (D median,vertebrae) ranged from 0.019 to 0.11 Gy/GBq. The median of cumulative absorbed dose across all 4 cycles was 1.3 Gy (range, 0.6-2.5 Gy). Hematologic toxicity was generally mild, with no grade 2 or higher toxicity for platelets, neutrophils, or hemoglobin. However, there was a decline in blood counts over time, with a fractional value relative to baseline at 6 mo of 74%, 97%, 57%, and 97%, for platelets, neutrophils, lymphocytes, and hemoglobin, respectively. Statistically significant correlations were found between a subset of hematologic toxicity markers and RM absorbed doses, both during treatment and at 3- and 6-mo follow-up. This included a correlation between the platelet count relative to baseline at 6-mo follow up: D median,vertebrae (r = -0.64, P = 0.015), D median,lumbar (r = -0.72, P = 0.0038), D median,thoracic (r = -0.58, P = 0.029), and D average,vertebrae (r = -0.66, P = 0.010), where D median,lumbar and D median,thoracic are median absorbed dose to the RM in the lumbar and thoracic vertebrae, respectively, within the FOV and D average,vertebrae is the mass-weighted average absorbed dose of all vertebrae. Conclusion: This study found a significant correlation between image-derived absorbed dose to the RM and hematologic toxicity, including a relative reduction of platelets at 6-mo follow up. These findings indicate that absorbed dose to the RM can potentially be used to understand and manage hematologic toxicity in peptide receptor radionuclide therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Blakkisrud J, Peterson AB, Wildermann SJ, et al. SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [177Lu]Lu-DOTATATE. J Nucl Med. 2024. PMID: 38548350. doi:10.2967/jnumed.123.266843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。